Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal

Prevention of Fibrosis Progression in CCl4-Treated Rats: Role of the Hepatic Endocannabinoid and Apelin Systems

Vedrana Reichenbach, Josefa Ros, Guillermo Fernández-Varo, Gregori Casals, Pedro Melgar-Lesmes, Teresa Campos, Alexandros Makriyannis, Manuel Morales-Ruiz and Wladimiro Jiménez
Journal of Pharmacology and Experimental Therapeutics March 2012, 340 (3) 629-637; DOI: https://doi.org/10.1124/jpet.111.188078
Vedrana Reichenbach
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josefa Ros
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillermo Fernández-Varo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregori Casals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pedro Melgar-Lesmes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teresa Campos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandros Makriyannis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel Morales-Ruiz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wladimiro Jiménez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 340 no. 3 629-637
DOI 
https://doi.org/10.1124/jpet.111.188078
PubMed 
22160265

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Received September 15, 2011
  • Accepted December 6, 2011
  • Published online February 14, 2012.

Article Versions

  • Earlier version (December 7, 2011 - 07:48).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Vedrana Reichenbach,
  2. Josefa Ros,
  3. Guillermo Fernández-Varo,
  4. Gregori Casals,
  5. Pedro Melgar-Lesmes,
  6. Teresa Campos,
  7. Alexandros Makriyannis,
  8. Manuel Morales-Ruiz and
  9. Wladimiro Jiménez
  1. Service of Biochemistry and Molecular Genetics, Hospital Clínic, Barcelona, Spain (V.R., J.R., G.F.-V., G.C., P.M.-L., T.C., M.M.-R., W.J.); Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain (V.R., J.R., G.F.-V., P.M.-L., M.M.-R., W.J.); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain (G.F.-V., M.M.-R., W.J.); Center for Drug Discovery, Northeastern University, Boston, Massachusetts (A.M.); and Department of Physiological Sciences I, University of Barcelona, Barcelona, Spain (W.J.)
  1. Address correspondence to:
    Dr. Wladimiro Jiménez, Servicio de Bioquímica y Genética Molecular, Hospital Clínic Universitari, Villarroel 170, Barcelona 08036, Spain. E-mail: wjimenez{at}clinic.ub.es
  1. This work was previously presented in part at the following conferences: Reichenbach V, Ros J, Fernández-Varo G, Muñoz-Luque J, Morales-Ruiz M, Makriyannis A, and Jiménez W (2008) Chronic stimulation of cannabinoid CB2 receptor represses fibrosis progression in CCl4-treated rats. 59th Annual Meeting of the American Association for the Study of Liver Diseases; 2008 Oct 31–Nov 4; San Francisco, CA. American Association for the Study of Liver Diseases, Alexandria, VA. Reichenbach V, Ros J, Fernández-Varo G, Casals G, Melgar-Lesmes P, Pauta M, Morales-Ruiz M, and Jiménez W (2010) Activation of the hepatic apelin system is of major relevance in early stages of liver fibrosis. International Liver Conference 2010; 2010 Apr 14–18; Vienna, Austria. European Association for the Study of the Liver, Geneva, Switzerland.

View Full Text

Statistics from Altmetric.com

Article usage

Article usage: December 2011 to June 2023

AbstractFullPdf
Dec 20111860109
Jan 2012800113
Feb 2012329985
Mar 20122552250
Apr 2012932626
May 2012822630
Jun 201254921
Jul 2012412121
Aug 2012411630
Sep 2012421327
Oct 2012462127
Nov 2012492444
Dec 201222528
Jan 2013501027
Feb 2013271025
Mar 2013413458
Apr 2013311628
May 2013362435
Jun 2013232918
Jul 2013171415
Aug 2013101518
Sep 2013112824
Oct 2013262235
Nov 201313119
Dec 2013221623
Jan 2014233329
Feb 2014231621
Mar 2014234236
Apr 2014292121
May 2014233427
Jun 2014221920
Jul 2014162114
Aug 2014223116
Sep 2014123434
Oct 2014183324
Nov 201417715
Dec 2014121714
Jan 2015161620
Feb 2015222324
Mar 2015301919
Apr 2015102214
May 2015201932
Jun 201582318
Jul 201592221
Aug 2015192013
Sep 2015162926
Oct 2015111123
Nov 2015151914
Dec 2015152620
Jan 2016324023
Feb 20169248
Mar 2016132220
Apr 20163217
May 2016182314
Jun 2016311118
Jul 2016191012
Aug 2016352212
Sep 2016361613
Oct 2016162718
Nov 2016152710
Dec 201693217
Jan 201735121
Feb 201753718
Mar 201723717
Apr 20174296
May 201703622
Jun 20171279
Jul 201743312
Aug 201723017
Sep 20172206
Oct 20172344
Nov 20170248
Dec 201722811
Jan 20180225
Feb 20181259
Mar 20180219
Apr 201804118
May 201813113
Jun 20180345
Jul 201823021
Aug 20181219
Sep 201832410
Oct 20181157
Nov 201832711
Dec 20182229
Jan 201964815
Feb 201934136
Mar 201944016
Apr 201961317
May 20191739
Jun 20191656
Jul 20192028
Aug 201947616
Sep 201975809
Oct 20193738
Nov 20193425
Dec 20192324
Jan 20201142
Feb 20202256
Mar 20201915
Apr 20202923
May 20204461
Jun 20203123
Jul 20203434
Aug 20201814
Sep 20201600
Oct 20202022
Nov 20202003
Dec 20202222
Jan 20213768
Feb 20213265
Mar 20213854
Apr 20213322
May 20212344
Jun 20212622
Jul 20211623
Aug 20212626
Sep 20212048
Oct 20212513
Nov 20214358
Dec 20213711
Jan 202229312
Feb 20222311
Mar 20222322
Apr 20223828
May 20222754
Jun 20221411
Jul 20222521
Aug 20223427
Sep 20223733
Oct 20222520
Nov 20222424
Dec 20222825
Jan 20233044
Feb 20233131
Mar 20231532
Apr 20231836
May 20231737
Jun 2023400

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 340 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 340, Issue 3
1 Mar 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Prevention of Fibrosis Progression in CCl4-Treated Rats: Role of the Hepatic Endocannabinoid and Apelin Systems
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal

Fibrosis Progression Prevention in CCl4-Treated Rats

Vedrana Reichenbach, Josefa Ros, Guillermo Fernández-Varo, Gregori Casals, Pedro Melgar-Lesmes, Teresa Campos, Alexandros Makriyannis, Manuel Morales-Ruiz and Wladimiro Jiménez
Journal of Pharmacology and Experimental Therapeutics March 1, 2012, 340 (3) 629-637; DOI: https://doi.org/10.1124/jpet.111.188078

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal

Fibrosis Progression Prevention in CCl4-Treated Rats

Vedrana Reichenbach, Josefa Ros, Guillermo Fernández-Varo, Gregori Casals, Pedro Melgar-Lesmes, Teresa Campos, Alexandros Makriyannis, Manuel Morales-Ruiz and Wladimiro Jiménez
Journal of Pharmacology and Experimental Therapeutics March 1, 2012, 340 (3) 629-637; DOI: https://doi.org/10.1124/jpet.111.188078
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • BI 685509 Reduces Portal Hypertension in TAA Cirrhosis Model
  • CGRP signaling in visceral organ cross sensitization
  • 20-HETE Synthesis Inhibitor Suppresses Renal Fibrosis
Show more Gastrointestinal, Hepatic, Pulmonary, and Renal

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics